British journal of cancer

Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas.

British journal of cancer

Raj N, Chan JA, Wang SJ, Aggarwal RR, Calabrese S, DeMore A, Fong L, Grabowsky J, Hope TA, Kolli KP, Mulvey CK, Munster PN, Perez K, Punn S, Reidy-Lagunes D, Von Fedak S, Zhang L, Bergsland EK

Response to 'Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study".

British journal of cancer

Johns LE, Jones ME, Schoemaker MJ, McFadden E, Ashworth A, Swerdlow AJ

Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study.

British journal of cancer

Munster P, Krop IE, LoRusso P, Ma C, Siegel BA, Shields AF, Molnár I, Wickham TJ, Reynolds J, Campbell K, Hendriks BS, Adiwijaya BS, Geretti E, Moyo V, Miller KD

Response to 'Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study".

British journal of cancer

Johns LE, Jones ME, Schoemaker MJ, McFadden E, Ashworth A, Swerdlow AJ

Reply to 'Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study".

British journal of cancer

Johns LE, Jones ME, Schoemaker MJ, McFadden E, Ashworth A, Swerdlow AJ

Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study.

British journal of cancer

Johns LE, Jones ME, Schoemaker MJ, McFadden E, Ashworth A, Swerdlow AJ

Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells.

British journal of cancer

Nikkilä J, Kumar R, Campbell J, Brandsma I, Pemberton HN, Wallberg F, Nagy K, Scheer I, Vertessy BG, Serebrenik AA, Monni V, Harris RS, Pettitt SJ, Ashworth A, Lord CJ

Menopausal hormone therapy and breast cancer: what is the true size of the increased risk?

British journal of cancer

Jones ME, Schoemaker MJ, Wright L, McFadden E, Griffin J, Thomas D, Hemming J, Wright K, Ashworth A, Swerdlow AJ

Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma.

British journal of cancer

Algazi AP, Weber JS, Andrews SC, Urbas P, Munster PN, DeConti RC, Hwang J, Sondak VK, Messina JL, McCalmont T, Daud AI

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer.

British journal of cancer

Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE

Pages